Chinese General Practice Experts Consensus on the Use of Benazepril Hydrochloride and Hydrochlorothiazide Tablets in Primary Care

doi:10.12114/j.issn.1007-9572.2021.00.440

Abstract

Abstract: Medical Doctor Association There is sufficient evidence that the fixed-dose single-pill combination can improve the therapy adherence and the rate of meeting the target blood pressure level in patients with hypertension，improving their prognosis.Benazepril hydrochloride and hydrochlorothiazide tablets（BHHT） have been used for hypertension for many years，which has proved to play a positive role in the treatment and management of hypertension in primary care by a great deal of clinical evidence.However，due to doubts about clinical use of BHHT，especially medicines containing hydrochlorothiazide，these medicines are underused seriously in primacy care by general practitioners（GPs）.To increase GPs’ understanding of BHHT and guide them to rationally use BHHT to promote standardized management of hypertension in primary care，China General Practitioner Association，Chinese Medical Doctor Association invited a panel of general practice experts to compile this consensus based on the latest high-quality evidence and relevant guidelines，which mainly includes characteristics and clinical benefits of BHHT，clinical application of BHHT in hypertension and hypertension with other diseases，and the main points for clinical application of BHHT in primary care，to guide the rational and standardized application of BHHT in primary care.

Key words: Hypertension, Benazepril hydrochloride and hydrochlorothiazide tablets, Single-pill combination, Expert consensus, Primary care, General practitioners

摘要： 固定配比的单片复方制剂已被证明可提高高血压患者治疗的依从性和血压控制率、改善患者预后。贝那普利氢氯噻嗪片用于治疗高血压已在国内外应用多年，积累了大量临床应用证据和经验，在基层高血压的治疗和管理中起到了积极作用，但目前基层全科医生在临床应用时尤其是对于含氢氯噻嗪成分药物的应用仍存在一些疑虑，导致应用不足现象比较严重。为进一步加强和指导基层全科医生认识并合理应用贝那普利氢氯噻嗪片，促进高血压在基层的规范化管理，中国医师协会全科医师分会特组织相关领域专家组成专家共识组，基于最新的高质量循证证据和国内外相关指南制定本共识，主要内容包括贝那普利氢氯噻嗪片的特点和临床获益、在高血压及高血压合并其他疾病中的临床应用和基层应用要点，以期指导基层全科医生合理规范化应用贝那普利氢氯噻嗪片。

关键词: 高血压, 贝那普利氢氯噻嗪片, 单片复方制剂, 专家共识, 基层, 全科医生

General Practitioner Branch of Chinese Medical Doctor Association. Chinese General Practice Experts Consensus on the Use of Benazepril Hydrochloride and Hydrochlorothiazide Tablets in Primary Care　[J]. Chinese General Practice, 2021, 24(11): 1309-1316. DOI: 10.12114/j.issn.1007-9572.2021.00.440.
中国医师协会全科医师分会. 贝那普利氢氯噻嗪片基层临床应用全科专家共识[J]. 中国全科医学, 2021, 24(11): 1309-1316. DOI: 10.12114/j.issn.1007-9572.2021.00.440.

References

［1］中国心血管健康与疾病报告编写组.中国心血管健康与疾病报告2019概要［J］．中国循环杂志，2020，35（9）：833-854．DOI：10.3969/j.issn.1000-3614.2020.09.001.
The Writing Committee of the Report on Cardiovascular Health and Diseases in China.Report on cardiovascular health and diseases in China 2019：an updated summary［J］．Chin Circ J，2020，35（9）：833-854．DOI：10.3969/j.issn.1000-3614.2020.09.001.
［2］WANG Z，CHEN Z，ZHANG L，et al．Status of hypertension in China：results from the China hypertension survey，2012-2015［J］．Circulation，2018，137（22）：2344-2356．DOI：10.1161/circulationaha.117.032380.
［3］陈伟伟，高润霖，刘立生，等．《中国心血管病报告2016》概要［J］．中国循环杂志，2017，32（6）：521-530．DOI：10.3969/j.issn.1000-3614.2017.06.001.
［4］ZHOU M G，WANG H D，ZENG X Y，et al．Mortality，morbidity，and risk factors in China and its provinces，1990-2017：a systematic analysis for the Global Burden of Disease Study 2017［J］．Lancet，2019，394（10204）：1145-1158．DOI：10.1016/S0140-6736（19）30427-1.
［5］刘明波，李镒冲，刘世炜，等．2010年中国人群高血压疾病负担［J］．中华流行病学杂志，2014，35（6）：680-683．DOI：10.3760/cma.j.issn.0254-6450.2014.06.014.
LIU M B，LI Y C，LIU S W，et al．Burden on blood-pressure-related diseases among the Chinese population，in 2010［J］．Chin J Epidemiol，2014，35（6）：680-683．DOI：10.3760/cma.j.issn.0254-6450.2014.06.014.
［6］GROUP S R，WRIGHT J T，WILLIAMSON J D，et al．A randomized trial of intensive versus standard blood-pressure control［J］．N Engl J Med，2015，373（22）：2103-2116．DOI：10.1056/NEJMoa1511939.
［7］SPRINT MIND INVESTIGATORS FOR THE SPRINT RESEARCH GROUP，WILLIAMSON J D，PAJEWSKI N M，et al．Effect of intensive vs standard blood pressure control on probable dementia：a randomized clinical trial［J］．JAMA，2019，321（6）：553-561．DOI：10.1001/jama.2018.21442.
［8］XIE X，ATKINS E，LV J，et al．Effects of intensive blood pressure lowering on cardiovascular and renal outcomes：updated systematic review and meta-analysis［J］．Lancet，2016，387（10017）：435-443．DOI：10.1016/s0140-6736（15）00805-3.
［9］WHELTON P K，CAREY R M，ARONOW W S，et al．2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APHA/ASH/ASPC/NMA/PCNA guideline for the prevention，detection，evaluation，and management of high blood pressure in adults：a report of the American College of Cardiology?American Heart Association task force on clinical practice guidelines［J］．J Am Coll Cardiol，2018，71（19）：e127-248．DOI：10.1016/j.jacc.2017.11.006.
［10］中国高血压防治指南修订委员会，高血压联盟（中国），中华医学会心血管病学分会中国医师协会高血压专业委员会，等．中国高血压防治指南（ 2018年修订版）［J］．中国心血管杂志，2019，24（1）：24-56．DOI：10.3969/j.issn.1007-5410.2019.01.002.
Writing Group of 2018 Chinese Guidelines for the Management of Hypertension，Chinese Hypertension League，Chinese Society of Cardiology，Chinese Medical Doctor Association Hypertension Committee，et al．2018 Chinese guidelines for the management of hypertension［J］．Chin J Cardiovasc Med，2019，24（1）：24-56．DOI：10.3969/j.issn.1007-5410.2019.01.002.
［11］王文，马丽媛，刘明波，等．初始低剂量氨氯地平加替米沙坦或复方阿米洛利联合治疗对高血压患者血压控制率影响的阶段报告［J］．中华心血管病杂志，2009，37（8）：701-707.
WANG W，MA L Y，LIU M B，et al．Effects of amlodipine plus telmisartan or amlodipine pins amiroride regimen on blood pressure control in hypertensive patients：preliminary report of Chinese Hypertension Intervention Efficacy（CHIEF） trial［J］．Chinese Journal of Cardiology，2009，37（8）：701-707.
［12］FELDMAN R D，ZOU G Y，VANDERVOORT M K，et al．A simplified approach to the treatment of uncomplicated hypertension：a cluster randomized，controlled trial［J］．Hypertension，2009，53（4）：646-653．DOI：10.1161/hypertensionaha.108.123455.
［13］HU D，LIU L，LI W.Efficacy and safety of valsartan/amlodipine single-pill combination in 11，422 Chinese patients with hypertension：an observational study［J］．Adv Ther，2014，31（7）：762-775．DOI：10.1007/s12325-014-0132-x.
［14］GRADMAN A H，PARISé H，LEFEBVRE P，et al．Initial combination therapy reduces the risk of cardiovascular events in hypertensive patients：a matched cohort study［J］．Hypertension，2013，61（2）：309-318．DOI：10.1161/hypertensionaha.112.201566.
［15］JAMERSON K，WEBER M A，BAKRIS G L，et al．Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients［J］．N Engl J Med，2008，359（23）：2417-2428．DOI：10.1056/NEJMoa0806182.
［16］PATEL A.Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus （the ADVANCE trial）：a randomised controlled trial［J］．Lancet，2007，370（9590）：829-840．DOI：10.1016/S0140-6736（07）61303-8.
［17］LINS R，AERTS A，COEN N，et al．Effectiveness of amlodipine-valsartan single-pill combinations：hierarchical modeling of blood pressure and total cardiovascular disease risk outcomes （the EXCELLENT study）［J］．Ann Pharmacother，2011，45（6）：727-739．DOI：10.1345/aph.1p663.
［18］《单片复方制剂降压治疗中国专家共识》专家组，中华医学会心血管病学分会高血压学组.单片复方制剂降压治疗中国专家共识［J］．中华高血压杂志，2019，27（4）：310-317.
Panel of Chinese Expert Consensus on Antihypertensive Therapy with Single-pill Combination，Chinese Society of Cardiology of the Chinese Medical Association.Chinese expert consesus on antihypertensive therapy with single-pill combination［J］．Chin J Hypertens，2019，27（4）：310-317.
［19］JAFFE M G，LEE G A，YOUNG J D，et al．Improved blood pressure control associated with a large-scale hypertension program［J］．JAMA，2013，310（7）：699-705．DOI：10.1001/jama.2013.108769.
［20］胡大一，刘力生，余金明，等．中国门诊高血压患者治疗现状登记研究［J］．中华心血管病杂志，2010，38（3）：230-238．DOI：10.3760/cma.j.issn.0253-3758.2010.03.007.
HU D Y，LIU L S，YU J M，et al．National survey of blood pressure control rate in Chinese hypertensive outpatients-China STATUS［J］．Chin J Cardiol，2010，38（3）：230-238．DOI：10.3760/cma.j.issn.0253-3758.2010.03.007.
［21］DAHL?F B.Further evidence for low-dose combinations in patients with left ventricular hypertrophy［J］．J Hum Hypertens，2005，19（Suppl 1）：S9-14．DOI：10.1038/sj.jhh.1001887.
［22］DAHL?F B，GOSSE P，GUéRET P，et al．Perindopril/indapamide combination more effective than enalapril in reducing blood pressure and left ventricular mass：the PICXEL study［J］．J Hypertens，2005，23（11）：2063-2070．DOI：10.1097/01.hjh.0000187253.35245.dc.
［23］陈源源，孙宁玲，余振裘，等．国产复方贝那普利/氢氯噻嗪治疗轻中度高血压的随机双盲多中心平行对照临床研究［J］．中国临床药理学杂志，2007，23（6）：407-411．DOI：10.13699/j.cnki.1001-6821.2007.06.006.
CHEN Y Y，SUN N L，YU Z Q，et al．Randomized double blind multicenter controlled clinical trial of fixed combination of benazepril and very low dose hydrochlorothiazide in the treatment of mild to moderate essential hypertension［J］．Chin J Clin Pharmacol，2007，23（6）：407-411．DOI：10.13699/j.cnki.1001-6821.2007.06.006.
［24］中国老年医学学会高血压分会．高龄老年人血压管理中国专家共识［Ｊ］．中国心血管杂志，2015，20（6）：401-409．DOI：10.3969 / j.issn.1007-5410.2015.06.001.
Hypertension Branch of Chinese Geriatric Medical Association.China experts consensus on the managements of hypertension in the very old people［J］．Chin J Cardiovasc Med，2015，20（6）：401-409．DOI：10.3969 / j.issn.1007-5410.2015.06.001.
［25］中国老年医学学会高血压分会，国家老年疾病临床医学研究中心中国老年心血管病防治联盟.中国老年高血压管理指南2019［J］．中华高血压杂志，2019，27（2）：111-135.
［26］BECKETT N S，PETERS R，FLETCHER A E，et al．Treatment of hypertension in patients 80 years of age or older［J］．N Engl J Med，2008，358（18）：1887-1898．DOI：10.1056/NEJMoa0801369.
［27］BANGALORE S，KAMALAKKANNAN G，PARKAR S，et al．Fixed-dose combinations improve medication compliance：a meta-analysis［J］．Am J Med，2007，120（8）：713-719．DOI：10.1016/j.amjmed.2006.08.033.
［28］《中国脑卒中防治报告》编写组.《中国脑卒中防治报告2019》概要［J］．中国脑血管病杂志，2020，17（5）：272-281．DOI：10.3969/j.issn.1672-5921.2020.05.008.
［29］GUAN T，MA J，LI M，et al．Rapid transitions in the epidemiology of stroke and its risk factors in China from 2002 to 2013［J］．Neurology，2017，89（1）：53-61．DOI：10.1212/wnl.0000000000004056.
［30］YONG H，FOODY J，LINONG J，et al．A systematic literature review of risk factors for stroke in China［J］．Cardiol Rev，2013，21（2）：77-93．DOI：10.1097/crd.0b013e3182748d37.
［31］赵连友，孙英贤，李玉明，等．高血压合并动脉粥样硬化防治中国专家共识［J］．中华高血压杂志，2020，28（2）：116-123．DOI：10.16439/j.cnki.1673-7245.2020.02.007.
［32］BAVISHI C，GOEL S，MESSERLI F H.Isolated systolic hypertension：an update after SPRINT［J］．Am J Med，2016，129（12）：1251-1258．DOI：10.1016/j.amjmed.2016.08.032.
［33］PROGRESS Collaborative Group.Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6，105 individuals with previous stroke or transient ischaemic attack［J］．Lancet，2001，358（9287）：1033-1041．DOI：10.1016/S0140-6736（01）06178-5.
［34］吴海英.新版美国高血压指南对我国高血压管理的启示［J］．中华高血压杂志，2018，26（12）：1108-1110．DOI：10.16439/j.cnki.1673-7245.2018.12.004.
［35］倪金迪，李响，刘梅，等．脑卒中及短暂性脑缺血发作的二级预防指南核心内容（2014年AHA/ASA版）［J］．中国临床神经科学，2015，23（1）：65-73．DOI：1008-0678（2015）01-0065-09.
NI J D，LI X，LIU M，et al．Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack（2014AHA/ASA edition）［J］．Chin J Clin Neurosci，2015，23（1）：65-73．DOI：1008-0678（2015）01-0065-09.
［36］Committee of Exports on Rational Drug Use National Health，Family Planning Commission of the People'republic of China，ASSOCIATION C P.Guidelines for rational use of drugs of heart failure（2 edition）［J］．Chin J Front Med Sci：Electron Version，2019，11（7）：1-78．DOI：10.12037/YXQY.2019.07-01.
［37］中华医学会心血管病学分会心力衰竭学组，中国医师协会心力衰竭专业委员会，中华心血管病杂志编辑委员会.中国心力衰竭诊断和治疗指南2018［J］．中华心血管病杂志，2018，46（10）：760-789．DOI：10.3760/cma.j.issn.0253-3758.2018.10.004.
［38］PONIKOWSKI P，VOORS A A，ANKER S D，et al．2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure：The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology （ESC）.Developed with the special contribution of the Heart Failure Association（HFA） of the ESC［J］．Eur J Heart Fail，2016，18 （8）：891 -975．DOI：10.1002/ejhf.592
［39］National Institute for Health and Care Excellence.Chronic heart failure in adults：diagnosis and management［EB/OL］．
［2020-10-21］．https：//www.nice.org.uk/guidance/ng106.
［40］ISIS-4：a randomised factorial trial assessing early oral captopril，oral mononitrate，and intravenous magnesium sulphate in 58，050 patients with suspected acute myocardial infarction.ISIS-4 （Fourth International Study of Infarct Survival） Collaborative Group［J］．Lancet，1995，345（8951）：669-685.
［41］Chinese Cardiac Study（CCS-1） Collaborative Group.Oral captopril versus placebo among 14，962 patients with suspected acute myocardial infarction：a multicenter，randomized，double-blind，placebo controlled clinical trial［J］．Chin Med J （Engl），1997，110（11）：834-8.
［42］SLEIGHT P.AngiotensinⅡ and trials of cardiovascular outcomes［J］．Am J Cardiol，2002，89（2）：11-16．DOI：10.1016/S0002-9149（01）02322-0.
［43］LONN E，YUSUF S，DZAVIK V，et al．Effects of ramipril and vitamin E on atherosclerosis：the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E （SECURE）［J］．Circulation，2001，103（7）：919-925．DOI：10.1161/01.cir.103.7.919.
［44］MESSERLI F H，MANCIA G，CONTI C R，et al．Dogma disputed：can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous?［J］．Ann Intern Med，2006，144（12）：884．DOI：10.7326/0003-4819-144-12-200606200-00005.
［45］SCHNABEL R B，YIN X Y，GONA P，et al．50 year trends in atrial fibrillation prevalence，incidence，risk factors，and mortality in the Framingham Heart Study：a cohort study［J］．Lancet，2015，386（9989）：154-162．DOI：10.1016/S0140-6736（14）61774-8.
［46］JANUARY C T，WANN L S，ALPERT J S，et al．2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation：a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society［J］．J Am Coll Cardiol，2014，64（21）：e1-76．DOI：10.1016/j.jacc.2014.03.022.
［47］WACHTELL K，HORNESTAM B，LEHTO M，et al．Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation：The Losartan Intervention For End Point Reduction in Hypertension （LIFE） study［J］．J Am Coll Cardiol，2005，45（5）：705-711．DOI：10.1016/j.jacc.2004.06.080.
［48］MAROTT S C，NIELSEN S F，BENN M，et al．Antihypertensive treatment and risk of atrial fibrillation：a nationwide study［J］．Eur Heart J，2014，35（18）：1205-1214．DOI：10.1093/eurheartj/eht507.
［49］HSIEH Y C，HUNG C Y，LI C H，et al．Angiotensin-receptor blocker，angiotensin-converting enzyme inhibitor，and risks of atrial fibrillation：a nationwide cohort study［J］．Medicine：Baltimore，2016，95（20）：e3721．DOI：10.1097/md.0000000000003721.
［50］YAO H，JIANG L，LIN X，et al．Fluvastatin combined with benazepril may contribute to the favorable prognosis of patients with atrial fibrillation［J］．Biomed Pharmacother，2016，83：687-692．DOI：10.1016/j.biopha.2016.07.031.
［51］ZHAO D，WANG Z M，WANG L S.Prevention of atrial fibrillation with renin-angiotensin system inhibitors on essential hypertensive patients：a meta-analysis of randomized controlled trials［J］．J Biomed Res，2015，29（6）：475-485．DOI：10.7555/jbr.29.20140149.
［52］SUO Y，ZHANG Y，WANG Y Y，et al．Renin-angiotensin system inhibition is associated with reduced risk of left atrial appendage thrombosis formation in patients with atrial fibrillation［J］．Cardiol J，2018，25（5）：611-620．DOI：10.5603/CJ.a2017.0112.
［53］HEALEY J S，BARANCHUK A，CRYSTAL E，et al．Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers：a meta-analysis［J］．J Am Coll Cardiol，2005，45（11）：1832-1839．DOI：10.1016/j.jacc.2004.11.070.
［54］李建平，孙志刚，张薇，等．贝那普利在心房颤动复律后维持窦性心律中的作用及其对左房功能的影响［J］．中华心血管病杂志，2005，33（1）：102．DOI：10.3760/j：issn：0253-3758.2005.01.029.
［55］王洪静.盐酸贝那普利（洛汀新）治疗心房颤动的临床研究［D］．长春：吉林大学，2010.
［56］何洪波，祝之明.我国糖尿病合并高血压的流行病学和治疗现状［J］．中国科学（生命科学），2018，48（8）：855-865．DOI：10.1360/N052018-00044.
［57］ZOUNGAS S，CHALMERS J，NEAL B，et al．Follow-up of blood-pressure lowering and glucose control in type 2 diabetes［J］．N Engl J Med，2014，371（15）：1392-1406．DOI：10.1056/NEJMoa1407963.
［58］ZHANG L X，WANG F，WANG L，et al．Prevalence of chronic kidney disease in China：a cross-sectional survey［J］．Lancet，2012，379（9818）：815-822．DOI：10.1016/S0140-6736（12）60033-6.
［59］ROBINSON B M，TONG L，ZHANG J Y，et al．Blood pressure levels and mortality risk among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study［J］．Kidney Int，2012，82（5）：570-580．DOI：10.1038/ki.2012.136.
［60］LIU J，ZHAO D，LIU J，et al．Prevalence of diabetes mellitus in outpatients with essential hypertension in China：a cross-sectional study［J］．BMJ Open，2013，3（11）：e003798．DOI：10.1136/bmjopen-2013-003798.
［61］DE BOER I H，BANGALORE S，BENETOS A，et al．Diabetes and hypertension：a position statement by the American diabetes association［J］．Diabetes Care，2017，40（9）：1273-1284．DOI：10.2337/dci17-0026.
［62］WHALEN J J.Definition of the effective dose of the converting-enzyme inhibitor benazepril［J］．Am Heart J，1989，117（3）：728-734．DOI：10.1016/0002-8703（89）90762-x.
［63］王先梅，杨丽霞，宋武战，等．盐酸贝那普利对自发性高血压大鼠肾脏纤维化的影响［J］．第四军医大学学报，2006，27（20）：1859-1862．DOI：10.3321/j.issn：1000-2790.2006.20.010.
WANG X M，YANG L X，SONG W Z，et al．Effect of benazepril on renal fibrosis in spontaneously hypertensive rats［J］．J Fourth Mil Med Univ，2006，27（20）：1859-1862．DOI：10.3321/j.issn：1000-2790.2006.20.010.
［64］BAKRIS G L，SARAFIDIS P A，WEIR M R，et al．Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events （ACCOMPLISH）：a prespecified secondary analysis of a randomised controlled trial［J］．Lancet，2010，375（9721）：1173-1181．DOI：10.1016/S0140-6736（09）62100-0.
［65］中华医学会，中华医学杂志社，中华医学会全科医学分会，等．高血压基层诊疗指南（2019年）［J］．中华全科医师杂志，2019，18（4）：301-313．DOI：10.3760/cma.j.issn.1671-7368.2019.04.002.
Chinese Medical Association，Chinese Medical Journals Publishing House，Chinese Society of General Practice，et al．Guideline for primary care of hypertension（2019）［J］．Chin J Gen Pract，2019，18（4）：301-313．DOI：10.3760/cma.j.issn.1671-7368.2019.04.002.

[1]	ZHANG Hanzhi, GE Xuhua, LU Yuan, JIN Hua, GUO Aizhen, CHEN Yuge, MA Linlin, PAN Ying, YU Dehua. Exploration and Differential Analysis of Continuing Education of General Practitioners' Clinical Thinking Ability Based on Working Competence [J]. Chinese General Practice, 2023, 26(34): 4315-4321.
[2]	HAO Aihua, ZENG Weilin, LI Guanhai, XIA Yinghua, CHEN Liang. Current Situation of the Construction of Family Doctor Team: an Investigation Based on the Perspective of General Practitioners [J]. Chinese General Practice, 2023, 26(34): 4261-4268.
[3]	LIAN Lu, CHEN Jiaying, WANG Xuanxuan, LI Yahui, ZHU Ya. Current Situation and Countermeasure of Medical Service Capacity of Primary Care Physicians in China [J]. Chinese General Practice, 2023, 26(34): 4246-4253.
[4]	ZHANG Shuai, LI Qin, LI Dongfeng, XIAO Jinping, LI Yunpeng. A Prospective Cohort Study of Solid Fuels Use and Risk of Hypertension in Chinese Older Adults [J]. Chinese General Practice, 2023, 26(32): 4001-4006.
[5]	ZHOU Dongdong, GE Xuhua. The Evaluation Index of Post Competence of General Practitioners in Less-developed Areas [J]. Chinese General Practice, 2023, 26(31): 3908-3914.
[6]	ZHOU Yingda, ZHUO Shuxiong, YANG Xi, JIN Hua, YU Dehua. Implementation Status and Strategy Research on the Construction of Clinical Pathways for Diagnosis and Treatment of Medically Unexplained Disease in Community General Practice [J]. Chinese General Practice, 2023, 26(31): 3939-3944.
[7]	XIAO Liqi, YANG Li, CUI Saixian, ZHANG Yayuan, WANG Yulu, HE Yan. Advances in the Association of High Salt-induced Gut Microbiota Disturbances with Salt-sensitive Blood Pressure [J]. Chinese General Practice, 2023, 26(29): 3704-3709.
[8]	CHEN Jing, ZOU Tao, ZHAO Danqing, XIAO Ziwen, WU Xianqing, Chinese Medical Association Psychosomatic Medicine Branch Perinatal Mental Disorders Collaborative Group. Expert Consensus on Screening, Diagnosis and Treatment of Perinatal Mental Disorders [J]. Chinese General Practice, 2023, 26(28): 3463-3470.
[9]	PU Haifeng, WANG Yinsheng, YU Changyin, CHEN Lingli, XIAO Xue, ZHANG Nian, CHEN Chuying, ZHU Jiming. Current Situation, Problems, and Strategies of Continuing Medical Education for Rural Order-oriented General Practitioners in Guizhou Province [J]. Chinese General Practice, 2023, 26(28): 3551-3558.
[10]	CHENG Xiaoran, ZHANG Xiaotian, LI Mingyue, CHENG Haozhe, TANG Haoqing, ZHENG Huixian, ZHANG Baisong, LIU Xiaoyun. Impact of Chronic Diseases Follow-up on Health Behaviors and Blood Pressure/Glucose Control of Patients with Hypertension and Diabetes in the Context of Treatment-prevention Integration [J]. Chinese General Practice, 2023, 26(28): 3482-3488.
[11]	GAO Yanli, WANG Hongjun, SUN Fei, JI Xiangqin, Changizi Roohollah. Exploration of Chronic Disease Management Model in Secondary Private General Hospital [J]. Chinese General Practice, 2023, 26(28): 3585-3590.
[12]	BIAN Lili, LI Xiaoxiao, DU Xueping, DAI Qinfang, WU Lin, SONG Beibei. Risk Stratification of Atherosclerotic Cardiovascular Disease and Lipid Goal Attainment in Hypertensive Patients Registered in Community [J]. Chinese General Practice, 2023, 26(27): 3388-3391.
[13]	ZHANG Lifeng, ZHANG Ningning, QIN Xiuqun, YANG Yi, ZHONG Dongmei, LIU Shaofei, DAI Yushen, WANG Xiaodan, WANG Mingfei. Healthcare-seeking Behavior and Influencing Factors of Children with Upper Respiratory Tract Infection in the Context of Hierarchical Medical System [J]. Chinese General Practice, 2023, 26(26): 3269-3275.
[14]	Expert group of expert consensus on the application of ulinastatin in common clinical critical illness. Expert Consensus on the Application of Ulinastatin in Common Clinical Critical Illness [J]. Chinese General Practice, 2023, 26(26): 3207-3219.
[15]	PAN Wen, FENG Jing, ZHENG Yanling, LEI Zihui, GAN Yong. Relationship between Psychological Capital and Intention to Stay among General Practitioners in China: the Mediating Role of Professional Identity [J]. Chinese General Practice, 2023, 26(25): 3127-3132.